• Home
  •  / Tonix Pharmaceuticals

Tonix Pharmaceuticals

OverviewSuggest Edit

Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

TypePublic
Founded2007
HQNew York, NY, USMap
Websitetonixpharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)16(+34%)
Share Price (Feb 2021)$1.5 (+23%)
Cybersecurity ratingAMore

Key People/Management at Tonix Pharmaceuticals

Seth Lederman

Seth Lederman

Co-Founder, CEO & Chairman
Jessica Edgar Morris

Jessica Edgar Morris

Chief Operating Officer
Margaret Smith Bell

Margaret Smith Bell

Director
Richard H. Bagger

Richard H. Bagger

Director
Gregory Sullivan

Gregory Sullivan

Chief Medical Officer
Daniel Goodman

Daniel Goodman

Director
Show more

Tonix Pharmaceuticals Office Locations

Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin
New York, NY, US (HQ)
509 Madison Ave
San Diego, CA, US
4225 Executive Square #250, La Jolla
Montréal, CA
317 1176 Rue Bishop
Dublin, IE
56 Fitzwilliam Square N
Show all (4)

Tonix Pharmaceuticals Financials and Metrics

Tonix Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(14.2m)

EBIT (Q2, 2020)

(14.2m)

Market capitalization (8-Feb-2021)

410.4m

Closing stock price (8-Feb-2021)

1.5

Cash (30-Jun-2020)

55.0m

EV

356.3m
Tonix Pharmaceuticals's current market capitalization is $410.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.2m4.1m6.2m9.0m12.7m10.4m7.9m8.8m10.6m

R&D expense

1.2m2.6m4.7m18.6m35.5m28.5m13.3m17.6m18.2m

Operating expense total

3.4m6.7m10.9m27.7m48.2m39.0m21.3m26.3m28.8m

EBIT

(3.4m)(6.7m)(10.9m)(27.7m)(48.2m)(39.0m)(21.3m)(26.3m)(28.8m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

316.01.1k762.7k1.0m1.1m1.3m1.1m1.6m2.0m2.2m2.9m2.9m3.0m3.3m2.3m2.1m2.1m2.0m1.9m1.8m2.1m2.3m2.4m2.4m2.8m2.6m3.6m

R&D expense

397.6k827.8k658.1k740.6k944.0k3.6m4.1m5.2m6.8m8.9m10.3m10.7m7.5m5.5m3.0m2.8m3.9m5.2m4.1m3.3m3.9m3.6m5.1m4.7m10.6m

Operating expense total

316.01.1k1.2m1.9m1.7m2.0m2.1m5.2m6.0m7.4m9.7m11.8m13.3m14.0m9.8m7.6m5.1m4.8m5.8m7.0m6.1m5.5m6.3m5.9m7.9m7.3m14.2m

Depreciation and amortization

5.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

41.1k1.8m8.2m38.2m19.2m18.9m25.5m25.0m11.2m

Accounts Receivable

598.6m

Prepaid Expenses

102.4k224.7k429.0k852.0k3.3m947.0k1.0m2.7m

Current Assets

143.6k2.0m8.6m39.0m46.4m27.1m26.4m26.1m13.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

747.0205.02.5m1.3m35.7k423.7k68.0k7.4m49.5m43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m34.4m29.3m19.3m16.7m14.7m16.4m12.2m10.0m30.7m55.0m

Prepaid Expenses

64.0k74.5k43.1k67.7k46.4k46.4k554.0k946.0k699.0k1.8m1.6m2.1m3.2m2.4m2.5m1.0m1.1m896.0k1.4m1.4m1.1m2.7m2.0m1.5m2.7m2.6m

Current Assets

2.6m1.4m78.7k491.4k114.4k7.5m50.1m44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m35.5m30.2m20.7m18.2m15.9m19.2m14.2m11.6m33.4m57.6m

PP&E

23.2k53.2k51.0k42.8k38.8k42.8k43.0k71.0k224.0k306.0k316.0k327.0k383.0k349.0k315.0k132.0k118.0k102.0k78.0k65.0k55.0k41.0k36.0k34.0k28.0k37.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.5m)(9.4m)(10.9m)(27.6m)(48.1m)(38.8m)(21.1m)(26.1m)(28.6m)

Depreciation and Amortization

9.3k14.3k17.0k36.0k161.0k339.0k70.0k54.0k26.0k

Accounts Payable

377.5k130.6k(60.0k)728.0k1.6m(2.2m)424.0k106.0k1.7m

Cash From Operating Activities

(2.6m)(5.7m)(8.5m)(22.8m)(42.5m)(37.3m)(19.1m)(24.0m)(26.7m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.5k)(2.3k)(2.0m)(5.1m)(6.8m)(2.0m)(4.1m)(7.2m)(5.2m)(11.2m)(18.6m)(9.7m)(21.4m)(34.7m)(14.0m)(23.8m)(31.4m)(5.1m)(9.8m)(15.6m)(6.9m)(13.0m)(18.5m)(6.2m)(12.1m)(19.9m)(7.3m)(21.5m)

Depreciation and Amortization

2.4k6.1k10.2k4.1k8.1k12.2k4.0k9.0k15.0k22.0k45.0k90.0k57.0k113.0k163.0k24.0k34.0k50.0k15.0k30.0k43.0k9.0k16.0k21.0k6.0k12.0k

Accounts Payable

(512.8k)(208.3k)2.2k44.3k635.4k160.0k635.0k754.0k1.7m502.0k1.3m948.0k(986.0k)(1.1m)(2.1m)(31.0k)307.0k490.0k(32.0k)342.0k(249.0k)(270.0k)(358.0k)(285.0k)(1.7m)118.0k

Cash From Operating Activities

(1.8m)(2.9m)(4.2m)(1.4m)(2.1m)(5.0m)(4.1m)(9.8m)(14.6m)(9.1m)(18.3m)(30.6m)(15.5m)(23.5m)(31.9m)(4.8m)(9.2m)(14.2m)(6.8m)(12.3m)(17.1m)(8.6m)(13.4m)(20.0m)(9.3m)(19.4m)
show all
USDQ2, 2011

Financial Leverage

-0.1 x
Show all financial metrics

Tonix Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

Learn more about our premium products
SecurityScorecard logo

Tonix Pharmaceuticals Online and Social Media Presence

Tonix Pharmaceuticals's Trends

Embed Graph

Tonix Pharmaceuticals News and Updates

January 14, 2021

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021
January 11, 2021

Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules

CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of…
January 05, 2021

Tonix Pharmaceuticals to Participate in Upcoming January Conferences

CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at four upcoming virtual co…
January 05, 2021

Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection

Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation
December 23, 2020

Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility

Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19
December 22, 2020

Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)

University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromes
Show more

Tonix Pharmaceuticals Blogs

February 08, 2021

Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

CHATHAM, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of…
February 08, 2021

Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Protocol Intradermal Test is Designed to Measure SARS-CoV-2 Specific Delayed Type Hypersensitivity (DTH), the Classic Method of Measuring T Cell Immunity to Tuberculosis and Other Pathogens Mult…
November 11, 2020

Tonix Pharmaceuticals to Participate in Upcoming November Conferences

CHATHAM, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to present at three upc…
September 29, 2020

Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis

Topline Results of Full Study Expected Fourth Quarter 2020 RELIEF Study Protocol Was Formally Amended Mid-Study to Conform to FDA Guidance During COVID-19 Public Health Emergency Currently Enrolled 503 Participants Represents More than Original Target of 470 Company is Currently Enrolling a Seco…
September 28, 2020

Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs

Facility Addresses the Shortage of Vaccine Production Capacity in the U.S. When Fully Operational the ADC Is Expected to be Capable of Manufacturing Clinical Trial Quality Vaccines, Including Vaccines Under Development for COVID-19 CHATHAM, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmac…
September 03, 2020

Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia

Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020 Positive Outcomes in Both Trials Would Support Submission of NDA in Second Half 2022 NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. …
Show more

 Tonix Pharmaceuticals Frequently Asked Questions

  • When was Tonix Pharmaceuticals founded?

    Tonix Pharmaceuticals was founded in 2007.

  • Who are Tonix Pharmaceuticals key executives?

    Tonix Pharmaceuticals's key executives are Seth Lederman, Jessica Edgar Morris and Margaret Smith Bell.

  • How many employees does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 16 employees.

  • Who are Tonix Pharmaceuticals competitors?

    Competitors of Tonix Pharmaceuticals include Savara Pharmaceuticals, ThermoGenesis and Precision Medicine Group.

  • Where is Tonix Pharmaceuticals headquarters?

    Tonix Pharmaceuticals headquarters is located at 509 Madison Ave, New York.

  • Where are Tonix Pharmaceuticals offices?

    Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin.

  • How many offices does Tonix Pharmaceuticals have?

    Tonix Pharmaceuticals has 4 offices.